IMVT
ImmunovantInc
ImmunovantInc historical holders
total: 2
Greenlight Capital ImmunovantInc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q1
David Einhorn has been an institutional investor in ImmunovantInc (IMVT) since 2026 Q1. According to 2026 Q1 report, David Einhorn holds 93,520 shares with a market value of roughly $2.32M representing 0.07% of their equity portfolio. The fund/company first acquired IMVT in 2026 Q1, initially purchasing 93,520 shares.
Does David Einhorn still hold IMVT?
Yes, David Einhorn continues to hold ImmunovantInc (IMVT). According to their 2026 Q1 report, they maintain a position of 93,520 shares valued at approximately $2.32M, representing 0.07% of their equity portfolio.
When did David Einhorn first invest in IMVT?
David Einhorn first invested in ImmunovantInc (IMVT) in 2026 Q1 at the reported quarter-end price of $24.84 per share, acquiring 93,520 shares in their initial purchase.
What is David Einhorn's average cost basis for IMVT?
Based on historical transaction data, David Einhorn's estimated cost basis for ImmunovantInc (IMVT) is approximately $24.84 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $24.84
IMVT transactions history by Greenlight Capital
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.07%
|
93,520
|
$24.84
|
$2,323,036
|
new
|
+0.07%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.